Ovid Therapeutics (OVID) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 41.3% versus a loss of 57.8%. Over five years, OVID leads with a -34.4% price change compared with -55.8% for SPRY. Ovid Therapeutics is the larger company by market cap ($457.0 million vs $453.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OVID | SPRY |
|---|---|---|
| Share price | $2.34 | $4.56 |
| Market cap | $457.00M | $453.48M |
| 1-day change | -0.85% | +4.59% |
| YTD return | +44.79% | -62.58% |
| 1-year return | +41.32% | -57.79% |
| 5-year return | -34.44% | -55.78% |
| EPS (TTM) | $-0.22 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.11 | $13.15 |
| 52-week low | $1.18 | $3.99 |
| Distance from 52-week high | -24.64% | -65.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +157.26% | +393.42% |
| Average volume | 1.58M | 1.85M |
| Shares outstanding | 195.30M | 99.45M |
| Employees | 23 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed SPRY by 99.1 percentage points over the past year.
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
OVID vs SPRY FAQ
Which is bigger, Ovid Therapeutics or ARS Pharmaceuticals?
Ovid Therapeutics (OVID) is larger, with a market capitalization of $457.00M compared with $453.48M for ARS Pharmaceuticals (SPRY).
Which stock has performed better over the past year, OVID or SPRY?
OVID returned +41.32% over the past 12 months, compared with -57.79% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Ovid Therapeutics and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.